DCRI Accomplishments showcases the publications, awards, and other achievements of our faculty members. Each quarter, a new collection will highlight the most recent accomplishments. During Spring 2026, DCRI faculty members were appointed to leadership roles in influential scientific and medical organizations, and received prestigious awards and notable promotions.

The Duke Clinical Research Institute (DCRI) and CardioVascular Clinical Trialists (CVCT) have announced a formal three-year partnership to establish a clear pathway to regulatory and clinical acceptance of cardiovascular prevention therapies. Titled "Pathway to Prevention," the initiative will unite stakeholders from academia, industry, government, nonprofits, and the technology sector to develop practical guidance to advance prevention indications.

Against the backdrop of two milestone anniversaries, the Duke Clinical Research Institute (DCRI) and Duke Clinical & Translational Science Institute (CTSI) came together to host a research symposium, “Trustworthy Translation – Stories of Today, Visions of Tomorrow,” focused on the practical application of putting evidence into practice to improve health.

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults. The AHA’s 2026 Heart Disease and Stroke Statistics Update reports that up to 13% of older adults hospitalized with heart failure with preserved ejection fraction may have ATTR‑CM, underscoring substantial opportunities to improve diagnosis in routine clinical care.